UK Markets closed

Hutchison China MediTech Limited (HCM.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
335.00+10.00 (+3.08%)
At close: 05:59PM GMT
Full screen
Previous close325.00
Open324.50
Bid328.50 x 0
Ask335.00 x 0
Day's range306.50 - 335.00
52-week range130.00 - 421.50
Volume38,420
Avg. volume292,620
Market cap2.897B
Beta (5Y monthly)0.62
PE ratio (TTM)N/A
EPS (TTM)-13.00
Earnings date01 Mar 2023 - 05 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.88
  • Globe Newswire

    HUTCHMED to Announce 2022 Final Results

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at 3:30 am Eastern Standard Time (EST) / 8:30 am Greenwich Mean Time (GMT) / 4:30 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

  • Globe Newswire

    HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

    — HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Europe and Japan planned to complete in 2023 — — Partnership approach aligned with HUTCHMED’s path to profitability and strategy to bring its innovative medicines to patients worldwide — — HUTCHMED to host a conference call and webcast at 8:30 a.m. EST (1:30 p.

  • Globe Newswire

    HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) adult patients with MET exon 14-skipping alterations who